Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert
The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Phila, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All resident physicians (RP) and nurse practitioners (NP) involved in inpatient care at two hospitals of the University of Pennsylvania
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: customized electronic alert
This intervention was not targeted to patients with a disease but to the providers.
The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a "reason for override" whenever the combination drugs of warfarin and NSAID were ordered together.
|
|
|
No Intervention: Standard practice
The control group was not patients but the providers.
Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Decreased rate of prescription of the combination of warfarin and NSAID
Time Frame: 17 months
|
17 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 803787
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warfarin and NSAID
-
NCT00287313CompletedAnticoagulants | Warfarin
-
NCT00735189Completed
-
NCT01657825CompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of S- and R-warfarin | Pharmacodynamics of Warfarin
-
NCT02050958CompletedNSAID Related Gastric Irritation
-
NCT07533266Not yet recruitingStudy to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic UlcerNSAID (Non-Steroidal Anti-Inflammatory Drug)
-
NCT01912066CompletedNSAID-associated Gastroduodenal Injury
-
NCT00700895UnknownIndications for Warfarin Therapy
Clinical Trials on Electronic Alert
-
NCT04394715CompletedHigh Risk Atherosclerotic Cardiovascular Disease
-
NCT03845660Completed
-
NCT04240678Completed
-
NCT07431931Not yet recruitingProteinuria | Glomerulonephritis | Referral and Consultation | Hematuria | Kidney Disease
-
NCT04791826CompletedHeart Failure | Diabetes Mellitus, Type 2